Wed, Feb 11, 2026
[Archive]
Volume 17, Issue 4 (December-2025 2025)
Iranian Journal of Blood and Cancer 2025, 17(4): 36-64 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rizvi B Z, Nag R, Raza S T, Srivastava S, Eba A, Rizvi S, et al . Gene Expression Profiling in Patients with CML Experiencing Loss of Treatment Response. Iranian Journal of Blood and Cancer 2025; 17 (4) :36-64
URL: http://ijbc.ir/article-1-1788-en.html
URL: http://ijbc.ir/article-1-1788-en.html
Butool Zahra Rizvi1 
, Riya Nag2 , Syed Tasleem Raza *3 , Sanchita Srivastava4 , Ale Eba4 , Saliha Rizvi4 , Naseem Fatima4 , Farheen Khan4
, Riya Nag2 , Syed Tasleem Raza *3 , Sanchita Srivastava4 , Ale Eba4 , Saliha Rizvi4 , Naseem Fatima4 , Farheen Khan4
1- Department of Biotechnology Khwaja Moinuddin Chishti Language University Lucknow, India.
2- Department of Biochemistry, Eras Lucknow Medical College and Hospital, Era University, Lucknow 226003, Uttar Pradesh, India.
3- Department of Biochemistry, Eras Lucknow Medical College and Hospital, Era University, Lucknow 226003, Uttar Pradesh, India. ,tasleem24@gmail.com
4- Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
2- Department of Biochemistry, Eras Lucknow Medical College and Hospital, Era University, Lucknow 226003, Uttar Pradesh, India.
3- Department of Biochemistry, Eras Lucknow Medical College and Hospital, Era University, Lucknow 226003, Uttar Pradesh, India. ,
4- Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
Abstract: (12 Views)
Chronic Myeloid Leukemia (CML) is a hematological malignancy characterized by the presence of the BCR-ABL1 fusion gene, which leads to uncontrolled proliferation of leukemic cells. Despite the effectiveness of Tyrosine Kinase Inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib in controlling CML, treatment resistance remains a major clinical challenge. The mechanisms contributing to resistance include BCR-ABL1 mutations, epigenetic modifications, and dysregulated microRNA (miRNA) expression. Gene expression profiling serves as a crucial tool for understanding disease progression, identifying novel therapeutic targets, and predicting treatment responses. This study explores the molecular basis of TKI resistance in CML through differential gene expression analysis, highlighting key biomarkers such as STAT5, BCL2L1 (Bcl-XL), MCL1, miR-150, and MYC. Additionally, we discuss emerging treatment strategies, including next-generation TKIs (asciminib, olverembatinib), non-BCR-ABL targeted therapies (mTOR inhibitors, JAK2 inhibitors, and HDAC inhibitors), and innovative approaches such as oncolytic viruses, exosome-based therapies, and CRISPR gene editing. Understanding the genetic and molecular landscape of CML can help optimize treatment strategies, improve early resistance detection, and advance personalized medicine for CML patients.
Keywords: Chronic Myeloid Leukemia (CML), BCR-ABL1, Tyrosine Kinase Inhibitors (TKIs), Drug Resistance, Gene Expression Profiling, Epigenetics, Personalized Medicine, Targeted Therapy.
: Review Article |
Subject:
Infectious Diseases
Received: 2025/10/11 | Accepted: 2025/12/12 | Published: 2025/12/30
Received: 2025/10/11 | Accepted: 2025/12/12 | Published: 2025/12/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
